NCT07091526Recruiting
Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 168 (estimated)
- First submitted
- 21 Jul 2025
- Start date
- 29 Jul 2025
- Primary completion date
- 29 Dec 2026
- Lead sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
- Diseases
- Pancreatic cancer
- NCT number
- NCT07091526
What you commit to
- Study type: Observational
- Planned participants: 168
- From 29 Jul 2025 to the primary completion date, 29 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No surgery was performed, or only palliative surgery/ biopsy was performed
- Patients who underwent emergency hemodialysis or plasma exchange after surgery
- A tyrosinase inhibitor was used
Other illness
- History of gout or long-term urate-lowering therapy, such as allopurinol
- Chronic kidney disease
- Oncolytic syndrome
Other
- Patients are missing follow-up data
- Hydrochlorothiazide and furosemide were used
- Hemolytic anemia
- Lead poisoning
- Hyperparathyroidism
- Hypothyroidism
- Patients with nonpancreatic primary tumors
- Pregnant or postpartum women.
Who the study is looking for
- Patients with pathologically confirmed pancreatic cancer (primary)
- Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
- The postoperative survival time was at least 6 weeks
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hepatopancreatobiliary Surgery Institute of Gansu Province Coordinator of this site? Confirm its status | Lanzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.